Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated falciparum malaria in mainland Tanzania, 2019

Table 4 Frequencies of analysed single-nucleotide polymorphism before treatment on day zero and on days of recurrent infections after treatment with artemether-lumefantrine

Visit day	SNPs (Frequencies, (pure + mix)/total*)
Visit day	pfk13	pfmdr1 N86	pfmdr1 184F	pfmdr1 D1246
D₀	10/311 (3.2%)	328/328 (100%)	108/328 (32.9%)	327/327 (100%)
R₀	0/42 (0%)	43/43 (100%)	24/43 (55.8%)	45/45 (100%)

D₀ first day of the study before treatment, R₀ Day of recurrent infection, *Total denotes the number of successful analysis

ISSN: 1475-2875